Money & Banking
RBI panel for up to 30 year fixed-rate loans, reasonable prepayment fine

Fixed rate long-term loan products with periodic interest reset (say every 7-10 years) may be...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation
LIC sells Dr Reddy's shares for Rs875 cr; cuts stake to 6.31%

Following the transaction, LIC’s total shareholding in Dr Reddy's Laboratories has come down to 6.31% from 8.38%

New Delhi: Pharmaceutical company Dr Reddy’s Laboratories said state-run Life Insurance Corporation of India (LIC) has cut its stake in the company to 6.31% by selling shares worth Rs875.29 crore in the open market, reports PTI.

 

LIC held 8.38% stake in the pharma major before offloading about 35.25 lakh shares, accounting for around 2.07% shareholding.

 

The insurer has reduced its stake to 6.31% through the open market sales, Dr Reddy’s Laboratories said in a filing to the BSE.

 

LIC has sold 35.25 lakh shares via market sale, the filing said.

 

Following the transaction, LIC’s total shareholding in the company has come down to 6.31% from 8.38%, it added.

User

Midcap crash: SEBI says ban on Ramkripa Securities to continue

The probe relates to a sharp plunge of 20%-26% in the shares of Parsvnath, Tulip Telecom, Glodyne Technoserve and Pipavav Defence & Offshore on 26th July on the BSE and NSE

Mumbai: Market regulator Securities and Exchange Board of India (SEBI) has said the restraining order on Ramkripa Securities, relating to the plunge in mid-cap stocks of four companies, would continue as the entity failed to give plausible explanation for its alleged trades, reports PTI.

 

Last year, the market regulator through an interim order had barred Ramkripa Securities from the securities market, following an initial probe into the steep decline in share prices of mid-cap stocks of Parsvnath, Tulip Telecom, Glodyne Technoserve and Pipavav Defence and Offshore Engineering.

 

“...the submissions of the noticee (Ramkripa Securities) do not give any plausible reason/explanation, at this stage, for its trades in the scrip of Glodyne as alleged in the interim order,” SEBI said in its order dated 18th January.

 

“I am of the considered view that no intervention is called for, at this stage, in either vacating the interim directions or modifying it, with respect to Ramkripa Securities Pvt Ltd,” SEBI’s whole-time member Rajeev Kumar Agarwal said.

 

The regulator said the probe in the matter is going on and appropriate action would be taken after its completion.

 

The probe relates to a sharp plunge of 20%-26% in the shares of on 26th July on the BSE and NSE.

 

These stocks witnessed sharp intraday price volume movement even though no major corporate announcements or price sensitive information was disclosed to the exchanges by these companies during the previous 15 days.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)